Achieve Life Sciences Inc. (SP4P)
XMUN 
Summary
SP4P Chart
Achieve Life Sciences: A Binary Bet With Cytisinicline And A Potential 2026 Launch
Achieve Life Sciences is a single-asset microcap centered on cytisinicline, with an accepted NDA and a June 20, 2026, PDUFA. Cytisinicline's α4β2 partial agonism aims to reduce cravings and blunt nicotine reward. In fact, the most promising aspect of cytisinicline was that its Phase 3 ORCA trials showed strong quit-rate deltas versus placebo.
Achieve Life Sciences: Could Be The Best 'Tobacco' Stock For 2026 - Strong Buy
Achieve Life Sciences is a late-stage Pharma company awaiting FDA approval for Cytisinicline, a novel (though proven) smoking cessation therapy, with a decision expected in June. Cytisinicline demonstrates superior efficacy and safety versus current treatments, with strong precedent in Europe and a large, underserved U.S. market. ACHV's market cap (~$250M) is a fraction of its potential, with peak sales for smoking and vaping cessation possibly reaching $2–3 billion.
Achieve Life Sciences, Inc. (ACHV) Q3 2025 Earnings Call Transcript
Achieve Life Sciences, Inc. ( ACHV ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Nicole Jones Richard A. Stewart - CEO & Executive Director Jaime Xinos - Chief Commercial Officer Mark Oki - Chief Financial Officer Jerry Wan - VP of Finance & Principal Accounting Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets, LLC, Research Division Gary Nachman - Raymond James & Associates, Inc., Research Division Brandon Folkes - H.C.
Achieve Life Sciences Inc. (SP4P) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Achieve Life Sciences Inc. ever had a stock split?
Achieve Life Sciences Inc. Profile
| Biotechnology Industry | Healthcare Sector | Richard A. Stewart CEO | XMUN Exchange | US0044685008 ISIN |
| CA Country | 25 Employees | - Last Dividend | 3 Aug 2017 Last Split | 13 Oct 1995 IPO Date |
Overview
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company engaged in the development and commercialization of therapeutic solutions for smoking cessation and nicotine addiction. Operating in Canada, the United States, and the United Kingdom, the company focuses on addressing the global smoking health epidemic through its innovative product, cytisinicline. Leveraging license agreements with entities such as Sopharma AD and the University of Bristol, Achieve Life Sciences is committed to providing a scientifically backed, plant-based alternative to nicotine replacement therapies. Based in Vancouver, Canada, the company aims to transform the treatment landscape for individuals looking to overcome nicotine dependency.
Products and Services
- Cytisinicline:
Achieve Life Sciences' flagship product, Cytisinicline, is a plant-based alkaloid with a mechanism of action that focuses on nicotine receptors in the brain. By interacting with these receptors, Cytisinicline aims to alleviate the severity of nicotine withdrawal symptoms, making it a promising therapy for individuals seeking to quit smoking. This innovative approach to smoking cessation underscores the company's dedication to addressing nicotine addiction with alternatives derived from nature, setting a new standard in the therapeutic domain.
